The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC

Although immune checkpoint and targeted therapies offer remarkable benefits for lung cancer treatment, some patients do not qualify for these regimens or do not exhibit consistent benefit. Provided that lung cancer appears to be driven by transforming growth factor beta signaling, we investigated th...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Oncol
Hlavní autoři: Marwitz, Sebastian, Turkowski, Kati, Nitschkowski, Dörte, Weigert, Andreas, Brandenburg, Julius, Reiling, Norbert, Thomas, Michael, Reck, Martin, Drömann, Daniel, Seeger, Werner, Rabe, Klaus F., Savai, Rajkumar, Goldmann, Torsten
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2020
Témata:
Oncology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6985561/
https://ncbi.nlm.nih.gov/pubmed/32039023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2019.01550
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky